





Synthesis and transformation of 












Dr. István Szatmári 





Institute of Pharmaceutical Chemistry 





















“If you want your children to be intelligent, read them fairy tales. If you want them to be more 



















1. INTRODUCTION ................................................................................................................................................. 1 
2. LITERATURE BACKGROUND ........................................................................................................................ 3 
2.1. NITROGEN-CONTAINING RING SYSTEMS ........................................................................................................ 3 
2.1.1. Pyridine- and pyrimidine-fused ring systems ..................................................................................... 4 
2.1.2. N-Bridgehead annulations .................................................................................................................... 9 
2.1.3. Five-membered B-ring derivatives .....................................................................................................16 
2.2. SULFUR-CONTAINING RING SYSTEMS ...........................................................................................................18 
2.3. OXYGEN-CONTAINING RING SYSTEMS ..........................................................................................................20 
3. RESULTS AND DISCUSSIONS ...........................................................................................................................22 
3.1. SYNTHESIS OF SUBSTITUTED KYNA DERIVATIVES ......................................................................................22 
3.1.1. Preparation of KYNA esters via the optimized Conrad–Limpach procedure ................................22 
3.1.2. Synthesis of hydroxy-functionalized KYNA derivatives ...................................................................22 
3.2. APPLICATION OF SYNTHESIZED KYNA DERIVATIVES IN MMR ...................................................................24 
3.2.1. Transformations of unsubstituted KYNA ethyl ester .......................................................................24 
3.2.2. Substituted KYNA ethyl esters applied in mMr ................................................................................25 
3.2.3. Diverse aminoalkylations of the hydroxylated KYNA derivatives ............................................................... 26 
3.2.3.1. 6-Hydroxykynurenic acid ethyl ester .............................................................................................................. 26 
3.2.3.2. 5-Hydroxykynurenic acid ethyl ester .............................................................................................................. 28 
3.2.3.3. 7-Hydroxykynurenic acid ethyl ester .............................................................................................................. 30 
3.2.3.4. 8-Hydroxykynurenic acid ethyl ester .............................................................................................................. 32 
3.2.3.5. DFT calculations on the reactivity of HO-KYNA derivatives ....................................................................... 34 
3.2.4. Extending the mMr to amide derivatives ...........................................................................................38 
3.3. BIOLOGICAL EVALUATIONS ON SYNTHESIZED AMIDES AND AMINOALKYLATED DERIVATIVES .................42 










Papers related to the thesis 
 
1. Mándi, Y.; Endrész, V.; Mosolygó, T.; Burián, K.; Lantos, I.; Fülöp, F.; Szatmári, I.; Lőrinczi, 
B.; Balog, A.; Vécsei, L. 
The opposite effects of kynurenic acid and different kynurenic acid analogues on tumor necrosis 
factor-α (TNF-α) production and tumor necrosis factor-stimulated gene-6 (TSG-6) expression in 
U-937 cells. 
Front. Immunol. 2019, 10, 1406, DOI: 10.3389/fimmu.2019.01406 IF.:5.085 
 
2. Fehér, E.; Szatmári, I.; Dudás, T.; Zalatnai, A.; Farkas, T.; Lőrinczi, B.; Fülöp, F.; Vécsei, L.; 
Toldi, J.  
Structural evaluation and electrophysiological effects of some kynurenic acid analogs. 
Molecules 2019, 24, 3502, DOI: 10.3390/molecules24193502  IF.:3.267 
 
3. Lőrinczi, B.; Csámpai, A.; Fülöp, F.; Szatmári, I. 
Synthesis of New C-3 Substituted Kynurenic Acid Derivatives. 
Molecules 2020, 25, 937, DOI: 10.3390/molecules25040937  IF.:3.267 
 
4. Molnár, K.; Lőrinczi, B.; Fazakas, C.; Szatmári, I.; Fülöp, F.; Kmetykó, N.; Berkecz, R.; Ilisz, 
I.; Krizbai, A. I.; Wilhelm, I.; Vécsei, L. 
SZR-104, a novel kynurenic acid analogue with high permeability through the blood–brain 
barrier. 
Pharmaceutics 2021, 13, 61, DOI: 10.3390/pharmaceutics13010061 IF.:4.421 
 
5. Lőrinczi, B.; Csámpai, A.; Fülöp, F.; Szatmári, I. 
Synthetic- and DFT modelling studies on regioselective modified Mannich reactions of 
hydroxy-KYNA derivatives. 
RSC Adv. 2021, 11, 543. DOI: 10.1039/d0ra08325a IF.:3.119 
 
6. Lo, Y-C.; Lin, C-L.; Fang, W-Y.; Lőrinczi, B.; Szatmári, I.; Chang, W-H.; Fülöp, F.; Wu, S-N. 
Effective activation by kynurenic acid and its aminoalkylated derivatives on M-type K+ current. 







7. Bálint Lőrinczi 
Kinurénsav-származékok továbbalakítása ortokinon-metid köztiterméken keresztül; 
XIII. Clauder Ottó memorial 
November 22. – 23. 2018. Budapest, Hungary 
 
8. Bálint Lőrinczi, Ferenc Fülöp and István Szatmári 
A kinurénsav C-3 helyzetének szubsztitúciója módosított Mannich-reakció segítségével 
Heterociklusos és Elemorganikus Kémiai Munkabizottság ülése 
June 3. – 5. 2019. Balatonszemes, Hungary 
 
9. Bálint Lőrinczi, István Szatmári and Ferenc Fülöp 
Synthesis and transformation of kynurenic acid derivatives 
19th Tetrahedron Symposium 
June 26. – 29. 2018. Riva del Garda, Italy 
 
10. Bálint Lőrinczi, Ferenc Fülöp and István Szatmári 
Synthesis of pyrroloquinolinone derivatives via ortho-quinonemethides 
26th Young Research Fellow Meeting 
February 20. – 22. 2019. Paris, France 
 
11. Bálint Lőrinczi, Ferenc Fülöp and István Szatmári 
Transformation of substituted kynurenic acid derivatives in modified Mannich reaction 
25th International Conference on Chemistry 







Tryptophan  -------------------------------------------------------------- TRP 
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KYNA (kynurenic acid) is an endogenous product of the tryptophan (TRP) metabolism, a 
pathway known to be responsible for the production of nicotinamide adenine dinucleotide (NAD) 
and NAD phosphate.1,2 In this pathway, TRP is converted into various compounds, including 
L-kynurenine, which can be metabolized in two separate ways. One furnishes KYNA, whereas the 
other gives 3-hydroxykynurenine and quinolinic acid, the precursors of NAD.3,4 
Among the important features of KYNA, one is that it is one of the few known endogenous 
excitatory amino acid receptor blockers with a broad spectrum of antagonistic properties in 
supraphysiological concentrations. One of its confirmed sites of action is the α-7-nicotinic 
acetylcholine receptor and, interestingly, the other, identified recently, is a higher-affinity positive 
modulatory binding site at the α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) 
receptor.5 
Since KYNA is a neuroprotective agent able to prevent neuronal loss following excitotoxic, 
ischemia-induced, and infectious neuronal injuries,6,7 there has recently been increasing interest in 
the synthesis and pharmacological studies of KYNA derivatives. The substitution of KYNA at 
positions 5–8 was achieved by starting from the corresponding aniline via the modified Conrad–
Limpach method.8-10 The hydroxy group at position 4 was transformed to ether10–12 or amine 
functions,13–15 while the carboxylic function at position 2 was mostly modified by synthesizing the 
corresponding esters10–12 or amides.16–21 
Formally, KYNA can be considered to be a nitrogen-containing 1-naphthol derivative. In 
our previous studies, 1-naphthol and its N-containing analogues were successfully applied in the 
modified Mannich reaction (mMr)22 leading to the corresponding aminonaphthols,23 
aminoquinolinols or aminoisoquinolinols.24,25 A similar transformation starting from xanthurenic 
acid has been described by Schmitt et al.26 They managed to perform regioselective 
aminoalkylation at position 3 on this substrate, by using benzyl protection of the C-8 hydroxyl 
group. 
Based on the evaluations of previous KYNA amides, a tertiary nitrogen is needed for 
biological activity towards the central nervous system.27–30 Derivatives bearing such functional 
groups can be synthesized by various methods, such as carboxyl amidation mentioned 
previously.16–21 An alternative route could be the transformation of the 4-hydroxy group into an 








My PhD work has been planned to accomplish two major goals. The first aim was to 
investigate the reactivity of kynurenic acid in a modified Mannich-type reaction. In the original 
Mannich reaction a C–H acid, formaldehyde and a secondary amine forms a so-called Mannich 
base in a relatively easy, one-pot reaction. Recently, one of its special variations, the mMr has 
gained ground, in which the C–H acid is replaced by electron-rich aromatic compounds such as 1- 
and 2-naphthols as active hydrogen sources.31 As KYNA can be considered to be a nitrogen-
containing 1-naphthol derivative, its reaction in the mMr also emerges as a straightforward version 
of functionalization. Using an array of amines and aldehydes, the reaction can yield the 
corresponding targeted aminoalkylated derivatives with the desired cationic center. 
 
The second aim of my work was to investigate the scope and limitations of the mMr on 
KYNA by reacting a representative amine and aldehyde with different functionalized or amide 
derivatives of KYNA. Reactions of a few selected amides and derivatives hydroxy-substituted at 
the B ring were studied further either by comparing different synthetic routes or through 








2. Literature background 
 
The modifications carried out on the 4-hydroxyquinoline-2-carboxylic acid skeleton can 
either be (i) additions of functional groups at different positions or (ii) modifications in the benzo-
fused 4-oxo-1,4-dihydropyridine-2-carboxylic acid skeleton itself, meaning the exchange of 
carbons to heteroatoms or the change of B ring size. While aspect (i) was already reviewed in 
2009,21 the modifications so far done on the B ring have not yet been collected. The aim of this 
section is to summarize the syntheses and use of KYNA derivatives modified at the B ring that are 
either containing a heteroatom in the B ring and/or have a different ring size (Figure 1). In the 
future, these compounds may provide a basis for the synthesis of new KYNA derivatives and thus 




The synthesis of modified quinoline structures has a wide variety of possible methods.32 
However, with the 2-carboxylic and 4-oxo functions taken into consideration, the possible routes 
are narrowed down to a small range of nucleophilic substitutions or additions followed by an 
intramolecular ring closure. Since the syntheses, from this aspect, differ only in a few cases, they 
have been categorized on the basis of the type and position of the heteroatom in the modified 
skeletons. 
 













2.1.1. Pyridine- and pyrimidine-fused ring systems 
A possible route for the preparation of functionalized quinoline structures is the Conrad–
Limpach synthesis. During the procedure described by Max Conrad and Leonhard Limpach, an 
aniline is reacted with β-keto esters to form an intermediate Schiff-base. In the second step, this 
intermediate undergoes a thermal intramolecular ring closure yielding the final quinolone 
derivative.33–35 As the synthesis of the intermediate can be achieved with several methods, 
variations of the reaction using different aniline derivatives or electrophiles to synthesize the 
intermediate have been disclosed. 
One of the first synthesis concerning the synthesis of KYNA derivatives bearing modified B 
rings has been published by Williamson et al. Presumably, since the described ethyl 
ethoxalylacetate would not yield the mentioned naphthyridine derivative, diethyl oxalacetate was 
used with aniline derivative 1a to carry out the synthesis of 2a. Then the product was stirred in 
boiling diphenyl ether (Ph2O) to achieve ring closure yielding 1,5-naphthyridine derivative 3a 
(Scheme 1, Table 1).36 
 
Scheme 1. Synthesis of 1,5-naphthyridine derivatives 3a,b 
Table 1. Reaction conditions for the preparation of 1,5-naphthyridine derivatives 











40-50 °C; r.t. 
4 h; over 
night 
2a 43%36 







r.t. 2.5 days 2b 23%38 
ii - 
Ph2O reflux 10+10 min 3a 84%
36 
Downtherm A 210 °C 5 h 3b 34%37 
Ph2O reflux 15+20 min 3b 29%
38 
 
The same method was utilized 50 years later by Nakamoto et al.37 and Feng et al.38 in two 







or its alkali salt, sodium (Z)-1,4-diethoxy-1,4-dioxobut-2-en-2-olate, respectively. The synthesized 
compounds were later transformed to potential antifungal37 and antimalarial49 or potential 
farnesoid X receptor modulators (Scheme 1 and Table 1).38,40 
In the case of the synthesis of 1,6-naphthyridine derivatives, the method presented in the 
literature, involves a procedure different from the one described by Conrad and Limpach. Pyridine 
with an active α-methyl function (4), that can be regarded as a acetophenone derivative,41 is 
reacted with dimethyl oxalate in the presence of excess MeONa needed to shift the reaction 
toward the ring closure (Scheme 2).42 
 
Scheme 2. Synthesis of naphthyridine derivative 6 via acetophenone analogue 4 
 
Regarding the synthesis of 1,7-naphthyridine derivatives, the literature is scarce: only two 
patents mention these compounds. In both cases, the derivatives were used to broaden the 
4-hydroxyquinoline-2-carboxylic acid scaffold of the final bioactive compound with an additional 
heteroatom-containing skeleton (8, 10, 11, 13, Scheme 3 and 4).43,44 However, the patents neither 
described the synthesis of the naphthyridine skeleton nor cited an appropriate reference. 
 








Scheme 4. 1,7-Naphthyridine derivatives (10, 11, 13) with possible acetyl coenzyme A inhibiting 
effect 
 
The synthesis of 1,8-naphthyridine, containing a carboxylic function at position C-2 and a 
hydroxy function at position C-4, was first carried out by Weiss et al. The reaction is a perfect 
example of Conrad–Limpach procedure using a substituted β-keto ester. For the formation of the 
Schiff base, α-ethoxalylpropionate (a β-keto ester) was applied yielding 16; however, its isolation 
in high purity was unsuccessful (Scheme 5).45 
 
 








The modification used in the synthesis of many KYNA derivatives46 was also applied for the 
synthesis of 1,8-naphthyridine derivatives. This method involves the use of acetylene derivatives 
for the synthesis of enamine intermediates through a Michael addition. Tonetti et al. utilized this 
method to synthesize 19 by applying dimethylacetylene dicarboxylate (DMAD) as an electrophilic 
reagent. However, the precise conditions of the synthesis are unclear, as the original paper could 
not be found and the reaction scheme was put forward based on the information gathered from 
Chemical Abstracts (Scheme 6).47 
 
Scheme 6. Proposed synthesis of 1,8-naphthyridine derivative 19 
 
However, judging from the work of Huc et al., it is safe to conclude that the reaction 
depicted in Scheme 7 is correct, since the research group managed to synthesize the same 
compound from the same starting materials (Scheme 7).48 Derivative 19 was later used to create 
oligomers, that were investigated in the hope of finding foldamers with a chemical space as vast as 
their aliphatic counterparts (namely, α-peptides).49–52 
 
 








The same method was applied by Dohmori et al. during the synthesis of different potentially 
antimicrobial agents (against Trichomonas vaginalis). Pyrrolidine-substituted 1,8-naphthyridine 
23 was synthesized using functionalized aminopyridine 21 and DMAD, albeit, a with a low yield 
of 11%. Nevertheless, it further supports the idea that these compounds can be synthesized with 
this modified Conrad–Limpach procedure (Scheme 8).53 
 
Scheme 8. Synthesis of pyrrolidine substituted 1,8-naphthyridine 23 
 
The use of DMAD to carry out the Michael addition and subsequently the synthesis of 
different pyrimidine-containing skeletons has also been investigated. The first method published 
describes the synthesis of pyrido[3,2-d]pyrimidine skeleton.54 This method was later optimized by 
Rosowsky et al. by decreasing the reaction time of the intramolecular ring closure from 45 
minutes to a reaction time as short as 3 minutes (Scheme 9).55 The method was later cited by 
patents for the synthesis of compounds exhibiting PI3K inhibitory activities.56 
 
Scheme 9. Synthesis of pyrido[3,2-d]pyrimidine derivative 26 
 
The synthesis of pyrido[2,3-d]pyrimidine skeleton has also been described; however, in the 
first publication it was only mentioned as a desired product. The research group tried to apply the 
same Michael addition with DMAD. However, the reaction yielded the C-5 carbonylated 
derivative of 6-aminouracil (28, Scheme 10).57 Sakaguchi et al. tried to achieve the ring closure by 
changing N,N-dimethylformamide (DMF) to MeOH. Still, both at room temperature and under 
reflux conditions, the formation of the same maleate intermediate 29 was observed. Subsequently, 
it was transformed in either DMF or in MeOH under reflux to 2-oxo-4-carboxylic acid derivative 
30. However, in MeOH the formation of a minimal amount of the 4-oxo derivative 31 also took 







ring closure steps [Downtherm A, 1,2-dichlorobenzene (DCB)] were not investigated, indicates 
that the synthesis with a better yield may be possible (Scheme 10).58 
 
Scheme 10. Possible methods for the synthesis of pyrido[2,3-d]pyrimidine derivative 31 
 
Dorokhov et al. used their method described for the synthesis of 1,6-naphthyridine 642 to 
synthesize a wide variety of pyrimidine analogues (33a,b, 34a–g) as well (Scheme 11).59 
 
Scheme 11. Synthesis of pyrido[2,3-d]pyrimidine derivatives 33a–g, 34a,b via acetophenone 
derivatives 32a–g 
 
2.1.2. N-Bridgehead annulations 
For the synthesis of 4H-pyrido[1,2-a]-pyrimidin-4-one skeleton, several methods have been 
described. Earlier reports include the reaction of 2-aminpyridine with different reagents under 
varied conditions ranging from reactions at 250 °C using Meldrum’s acid60 through reactions in 
AcOH (under reflux conditions)61 or with the use of metal catalysts62 to milder reactions in 
ethanol at reflux temperature.63 However, the synthesis of quinoline compounds bearing both the 







In this subsection, methods available for the synthesis of the specific skeleton until now are 
collected. 
As a straightforward approach, the Conrad–Limpach procedure can also be applied to 
synthesize the required derivatives. Diethyl 2-methyl-3-oxosuccinate, as a functionalized β-keto 
ester was used by Jaenicke et al. along with bismuth trichloride as catalyst to synthesize KYNA 
analogue 36, methyl-substituted at C-3 containing bridgehead nitrogen (Scheme 12). Regarding 
catalysts, the reaction showed high selectivity toward bismuth trichloride compared to other salts, 
such as zinc chloride or iridium chloride.64 
 
Scheme 12. Synthesis of C-3 functionalized N-bridgehead derivative 36 using metal catalyst 
 
It has been shown in two articles that the synthesis can also be carried out without the use of 
a toxic metal catalyst. Starting from the same β-keto ester, the synthesis of both 36 and the 6-
bromo-substituted derivative 38 could be achieved (Scheme 13).65,66 Though the inaccurate 
description of the methods (not given w/w% and mol% of TsOH-SiO2 catalyst) and the lower 
yields overshadow the results. 
 
Scheme 13. Metal-free synthesis of compound 36 and its bromo-substituted derivative 38 
 
Similar to the synthesis of pyridine-fused derivatives, the β-keto ester electrophile can be 
replaced by other electron-deficient reagents, such as DMAD. One of the reactions described used 
the acetylene derivative in water. The reaction carried out at room temperature yielded the 







applied in a patent to create derivatives inhibiting MeTTL3 activity, and in this way proliferative 
disorders, such as cancer, autoimmune, infectious or inflammatory diseases.68 
 
Scheme 14. Synthesis of unsubstituted N-bridgehead derivative 40 
 
A similar procedure was used by Summa et al.69,70 to synthesize 3-hydroxy-containing 
9aH-pyrido[1,2-a]pyrimidine derivatives (Scheme 15). Based on the Conrad–Limpach procedures 
using DMAD as described in previous paragraphs, it is expected that the first step would involve 
the enamine formation of the acetylene and the amino group. However, based on their previous 
experiences with the synthesis of hydroxypyrimidinones, the formation of an O-adduct 
intermediate was expected. This could possibly be a 2-aminopyridine-N-oxide regarded as the 
tautomer of amidoxime. These derivatives are known to react with DMAD to form O-adducts 
(vinylhydroxylamines).71,72 The subsequent rearrangement/cyclization of 42a,b took place in 
o-xylene under reflux. However, the isolation of the product was not described, since it was 
further transformed without isolation into its pivalate derivative (43a) in order to facilitate its 
purification. The procedure was successfully broadened to other aminopyridine derivatives as 
well, with N-oxidation of the aminopyridines. It is interesting to mention that in the case of 43c, 
the described final synthesis using p-toluenesulfonic acid (pTsOH) as catalyst, was performed in 
a single step, providing the lowest yield. 
 
Scheme 15. Synthesis of C-3 aryl- and alkoxy-substituted derivatives 43a–c 
 
Furthermore, in addition to DMAD, the synthesis of the same C-3 hydroxy-functionalized 
compounds can be achieved through the use of a different electrophile, namely, dimethyl 







2-hydroxy-pyrido[1,2-a]pyrimidin-4-on-2-carboxylic acid derivatives (45a,b, Scheme 16).73 The 
method was later applied for the synthesis of different HIV-1 integrase inhibitors.74–76 
 
Scheme 16. Synthesis of C-3 hydroxy-substituted N-bridgehead derivatives 45a,b 
 
In continuing the discussion of reactions utilizing acetylenes to yield the desired 
pyrido[1,2-a]pyrimidin skeleton, DMAD can also be reacted with nucleophiles derived from 
unique compounds. An interesting alternative method was investigated by Rees et al. using 
1,2,4-triazolo[4.3-a]pyridine as nucleophile (Scheme 17).77 Among other reaction routes yielding 
different products, DMAD can react with the N-1 atom of the triazole ring, yielding intermediate 
47a delivering 48 through a ring-opening and subsequent intramolecular ring-closure. 
 
Scheme 17. Synthesis of N-bridgehead KYNA derivative 48 via ring-member extension 
 
Even though previous methods described above give possibilities for the synthesis of C-3-
substituted derivatives, further functionalization can be achieved through the method reported by 
Ackermann et al.78 Starting from 2-pyridylhydrazone 49 and alkyne 50a,b, manganese-catalyzed 
carbonylative annulations yielding compounds 36 and 51 were carried out (Scheme 18). The 
method was mainly used for the synthesis non-carboxylic derivatives; however, judging from the 
number of available acetylene derivatives, this reaction may provide a useful approach to 








Scheme 18. Synthesis of derivatives 36 and 51 via a manganese-catalyzed reaction 
 
One of the first publications regarding the synthesis of the pyrido[1,2-a]-pyrimidine skeleton 
was published in 1969 by Sturm et al.79 An azide derivative, a special nucleophile, was used as 
starting compound upon reacting with either dimethyl fumarate (64% product yield) or dimethyl 
maleate (59% yield). The following steps were proposed for a possible mechanism. First, tautomer 
52b reacts with one of the electrophiles through a Diels–Alder type forming a 5-membered ring. 
In subsequent ring opening and elimination of N2, enamine intermediate 39 is formed which, after 
a thermally driven ring closure, gives 40 as the final product (Scheme 19). The reaction between 
aminopyridine and acetylenedicarboxylic acid esters resulting in the same enamine (39) and 
giving the same product (40) after cyclization at 140 °C, was also mentioned. However, neither its 
synthesis was described nor a related literature reference was cited. 
 
Scheme 19. Synthesis of 40 from an azide starting compound 
 
The use of malonic acid derivatives was also applied to synthesize derivatives bearing C-3 
substitutions. However, this method requires further modifications, since ring closure yields only 
2-hydroxy derivative 54, that needs to be oxidized (Scheme 20).80 Even though the procedure 
itself is not as elegant as the previous ones, the use of functionalized anilines and malonic acids 
may yield a wide range of derivatives. 
 








It is worth mentioning that the formation of the pyridine-fused pyrimidine skeleton has also 
been observed during the pyrolysis of an isoxazoline-substituted isoquinoline (59). The research 
group investigated the photolysis of different isoxazoline-substituted derivatives. When the 
photolysis of 59 was changed to pyrolysis in a scale-up study, the formation of 61 was observed 
(Scheme 21).81 
 
Scheme 21. Pyrolytic decomposition of compound 59 yielding N-bridgehead derivative 61 of 
KYNA 
 
Six-membered heterocycles containing more heteroatoms have reduced reactivity toward 
electrophiles. As a consequence, during the synthesis of KYNA skeletons with pyridazine, 
pyrimidine or pyrazine moieties, aniline starting materials may require further modifications. One 
such modified method applied by Mátyus et al. uses DMAD and the accompanying 
aminopyridazine is substituted with electron-donating groups (EDG). However, beside electron 
donation, further factors may be present, as ring closure led to the formation of the desired 
pyrimido[1,2-b]pyridazin-2-one derivative only in the case of the hydroxy-substituted starting 
compound (64a). The morpholino group yielded 2-oxo-4-carboxylate analogues, similar to the 








Scheme 22. Synthesis of pyrimido[1,2-b]pyridazine derivative (64a) of KYNA 
 
The research group also noted this difference as an anomaly, based on a previous work.84 
These pieces of information and results with electron-density calculations support the conclusion 
that the favored reaction would be a nucleophilic addition on C-3 of DMAD. 
Koomen et al.85 also used DMAD to synthesize adenosine derivatives bearing fluorescent 
attributes (Scheme 23). The starting 2’-deoxyadenosine compound 65 can be considered to be an 
imidazole-fused 6-aminopyrimidine. As previously mentioned, pyrimidine derivatives should be 
less reactive and thus unwilling to undergo the Michael addition; however, the imidazole ring may 
induce an excess of electron of the pyrimidine ring and promoting the reaction. 
 
Scheme 23. Synthesis of adenosine derivative 66 
 
The work of Kang-Chien et al.86 also seems to support the hypothesis that an electron-
donating substituent favors the Michael addition. The synthesis of a special tetracyclic quinoline 
derivative [4(1H)-oxopyrimido[1,2-a]perimidine-2-carboxylate, 68] was carried out starting form 
2-aminoperimidine that can be considered as a to be 2-aminopyrimidine fused with naphthalene. 







prominent electron-donating quality. Consequently, the reaction could be carried out in MeOH 
(Scheme 24). 
 
Scheme 24. Synthesis of perimidine derivative 68 
 
The work of Jain et al. can be regarded as a further development of the study by Sturm et al 
described in Scheme 19 except that it was implemented in the synthesis of bridgehead 
derivatives.87 Though via a different procedure, an azide intermediate was generated in both 
studies and then it was reacted further with a fumaric acid ester (in this case diethyl fumarate, 
DEF). Beside the hypothesized steps described by Sturm et al., an alternative route have also been 
proposed. First, the decomposition of the azide function takes place and then a subsequent DEF 
attack provides an aziridine ring that opens up to give the enamine intermediates 71a–c (Scheme 
25). 
 
Scheme 25. Synthesis of indole-fused N-bridgehead derivative 72a–e from azide starting 
compounds 
 
2.1.3. Five-membered B-ring derivatives 
Since five-membered heterocyclic compounds have an excess of electrons, the modified 
Conrad–Limpach procedure applying DMAD or DEAD (diethyl acetylenedicarboxylate) for 
intermediate formation and its subsequent ring closure can be easily carried out. Both pyrrolo[2,3-
b]pyridine and pyrrolo[3,2-b]pyridine ring systems have been synthesized in a similar way. Grinev 
et al. used the potassium salt of 3-aminoindole-2-carboxylic acid in glacial acetic acid yielding 3-
aminoindole in situ that subsequently reacted with DEAD (Scheme 26).88 The reaction yields δ-
carbolines 76a–c similar to the reactions described by Guyot et al. reporting the synthesis of α-








Scheme 26. Synthesis of δ-carboline KYNA derivatives 76a–c 
 
It is interesting to note that in both cases, probably as the consequence of the high 
nucleophility of indole, formation of side-products was also reported. In the synthesis of 
δ-carbolines, pentacyclic aromatic compounds appeared bearing an additional indole structure. In 
the case of α-carboline derivatives, in turn, Guyot et al. used N-methyl-2-aminoindole to 
presumably inhibit the formation of bridge-head nitrogen-containing derivatives. It was not 
directly specified by Guyot et al. whether it was for this reason. Nevertheless, in the following 
paragraphs, they described the synthesis of a derivatives, where the ring closure takes place at the 
unsubstituted N-1 atom. 
 
Scheme 27. Synthesis of α-carboline KYNA derivative 79 
 
The same Conrad–Limpach procedure can also be used for the synthesis of the 
pyrrolo[3,4-b]pyridine skeleton. Silva et al. prepared a tetraphenylporphin (tPorphin) compound 
containing the pyridine-2-carboxylic acid moiety fused to one of the pyrrole rings of the porphin 
skeleton (82a,b, Scheme 28).90 
 












Both six- and five-membered derivatives have been synthesized. Kitao et al. used a modified 
Conrad–Limpach procedure, utilizing DMAD to form enamine intermediates (84a–c). Ring 
formation was carried out in Ph2O (Scheme 29).
91 
 
Scheme 29. Synthesis of 4H-thiopyrano[3,2-b]pyridine derivatives 85a–c 
 
Baron et al. fabricated a wide variety of excitatory amino acid antagonists with the six-
membered B ring of KYNA changed to a five-membered sulfur-containing ring. The synthesis of 
these compounds is similar to that of the six-membered skeleton, utilizing DMAD or DEAD in the 
first step with the corresponding aminothiophenes (86,89). The subsequent intramolecular ring 
closure was carried out in Ph2O, nujol or polyphosphoric acid (Scheme 30).
92 Unfortunately, no 








Scheme 30. Synthesis of thiophene derivatives 88a,b, 92a,b and 93a,b 
 
Though the method described in Scheme 30 has the most detailed description, it is not the 
only one. The synthesis of a thieno[3,2-b]pyridine system was already published earlier. Here, 
similar to the δ-carboline derivatives,88 DEAD was used yielding the thieno analogue (95) of δ-
carboline derivative 76b (Scheme 31).93 
 
Scheme 31. Synthesis of the thieno analogue of δ-carboline derivative 76b 
 
The thieno[3,4-b]pyridine skeleton was already mentioned earlier. However, in this work, 
the synthesis yield was not reported (Scheme 32).94 
 











Regarding pyrano ring systems, it must be emphasized that in contrary to nitrogen-bearing 
systems, the aromaticity of the compounds is lost. Whereas the procedures described in the 
following paragraphs indicate that efficiency of the synthesis is not affected, the potential 
biological activity may vary substantially in comparison with KYNA. 
Kitao et al. based their procedure for the thiopyrano derivatives92 on the work of 
Strandtmann et al. who synthesized 1,5-dihydro-4,10-dioxobenzopyranopyridine-2-carboxylic 
acid derivatives 101a–c (Scheme 33).95 
 
Scheme 33. Synthesis of benzopyranopyridine derivatives 101a–c 
 
Dorokhov et al., beside synthesizing the pyridine- and pyrimidine-fused derivatives with the 
use of acetophenones,41,42 also achieved the synthesis of pyranone derivatives. Pyranones 102a–c 
bearing the crucial active α-methyl function, similar to the ones used for pyridine- and pyrimidine-
fused derivatives synthesized previously, were reacted with diethyl oxalate in the presence of 
sodium ethoxide (Scheme 34).96 
 








The method used by Strandtmann et al. in the synthesis of benzopyrano[2,3-b]pyridine 
derivatives mentioned above was extended by the research group to synthesize 
benzopyrano[3,4-b]pyridine derivatives (106a–c, Scheme 35).95 The triazol derivatives of these 
compounds have been patented for their possible useful application in allergic manifestations such 
as bronchial asthma, hay fever, etc.97 
 
Scheme 35. Synthesis of pyrano[3,4-b]pyridine derivatives 106a–c 
 
Regarding the furan-fused 4-oxopyridine-2-carboxylic acid derivatives, the only synthesis 
mentioned describes a procedure similar to that applied in the synthesis of δ-carbolines reported 
earlier.89 Using a potassium salt of 3-aminobenzofuran-2-carboxylic acid (107) and DMAD, 
compound 108, the furan analogue of δ-carboline 76b could be synthesized (Scheme 36).98 
 







3. Results and discussions 
 
3.1. Synthesis of substituted KYNA derivatives 
 
3.1.1. Preparation of KYNA esters via the optimized Conrad–Limpach 
procedure 
 
For the modified Mannich reactions to be carried out, KYNA and its derivatives were 
needed. In the case of KYNA, the synthesis of the required ethyl 4-hydroxyquinoline-2-
carboxylate (111a) derivative has already been published.99 In the described process, aniline was 
reacted with diethyl acetylenedicarboxylate forming the intermediate enamine. The second ring-
closing reaction in Ph2O at 250 °C led to the formation of the ethyl ester in an overall yield of 
58%. In our case, the following optimizations were applied: (i) after the formation of enamine 
110a, column chromatography was used to purify the intermediate; (ii) Ph2O was replaced by 
DCB that has lower boiling point (180 °C) allowing an easier work-up procedure. These modified 
conditions led to the formation of 111a in an overall yield of 67% (Scheme 37). The same 
procedure was used for the synthesis of KYNA derivatives, alkyl-, aryl-, and halogen-substituted 
at the B ring (111b–e) as well. It is interesting to mention that in the case of starting material 109b, 
two regioisomers formed with a ratio of 1:2 (111c:111d). 
 
Scheme 37. Synthesis of KYNA ethyl ester.  
 
3.1.2. Synthesis of hydroxy-functionalized KYNA derivatives 
 
Although the synthesis of the methyl esters of hydroxy derivatives are described in 
the literature,100,101 ethyl esters were chosen for several reasons. By carrying out their mMr, 
they provided a better basis for comparison with previous derivatives. Furthermore, by 







derivatives (114a–c) were synthesized with the Conrad–Limpach method applying the 
optimizations refined in previous investigations (Scheme 38). 
 
 
Scheme 38. Synthesis of hydroxykynurenic acid derivatives 
 
As a last step, an additional column chromatographic purification of the esters was 
also required. The reason is that during the synthesis, even with the application of DEAD 
instead of the methyl derivative, maleimide side-products were formed in high yields. The 
literature describes the formation of these compounds as side-products during certain 
Conrad–Limpach reactions.102–104 However, in our case, probably due to the higher 
reactivity of hydroxyanilines, the synthesis were shifted toward the formation of the 
maleimides. After purification, the desired hydroxy esters were isolated in moderate yields. 
Note that the synthesis starting from m-aminophenol allowed the isolation of the two 
possible regioisomers with a final ratio of 1:2 (114b:114c) similar to that of derivatives 
111c:111d. 
Based on the work of Sutherland et al.,105 p-TsOH as catalyst was investigated in a 
one-pot version of the Conrad–Limpach procedure applying microwave irradiation 
(Scheme 38). The synthesis provided the appropriate hydroxy derivatives in increased 
yields with diminished maleimide formation and the work-up could be carried out without 
time-consuming chromatography. 
Compound 117a was synthesized by the esterification of 8-hydroxykynurenic acid 
(xanthurenic acid, 115) as it was commercially available (Scheme 39). This step was 
needed to avoid the direct use of poorly soluble xanthurenic acid and to obtain information 








Scheme 39. Esterification of xanthurenic acid (115) 
 
It is interesting to mention that the esterification was first carried out according to a 
literature method used for the synthesis of the methyl ester.106 The use of EtOH as solvent 
led to the isolation of 4-ethoxy-substituted ethyl ester 116a. Since methanol was used for 
the synthesis described in the literature cited above, the reaction was repeated in this 
solvent. In a similar manner, under these conditions, methoxy-substituted methyl ester 
116b could be isolated. As suggested also by the literature, 116a and 116b should have 
been formed during the esterification by thionyl chloride in EtOH or MeOH.107 In our 
hands, however, employing these conditions, both esters (117a,b) could be obtained in 
good yields, without being contaminated by the corresponding 4-alkoxyquinoline. 
 
3.2. Application of synthesized KYNA derivatives in mMr 
 
3.2.1. Transformations of unsubstituted KYNA ethyl ester 
 
The ethyl ester of 4-oxo-1,4-dihydroquinoline-2-carboxylate (111) was first reacted with 2-
morpholinoethylamine in the presence of aqueous formaldehyde (22% solution). The reaction was 
conducted in different solvents [acetonitrile (MeCN), DMF, EtOH, and 1,4-dioxane] at different 
temperatures (60 °C, 80 °C, and 110 °C). The optimized reaction conditions were found to be 
reflux temperature, using 1,4-dioxane as solvent, and 5 h reaction time. All reaction conditions led 
to the formation of 118 as the single product. It is interesting to note that the medium was basic 
enough to lead to the hydrolysis of the ester function (Scheme 40). 
To explore the scope and limitation of the transformation, 111 was reacted with N,N-
dimethylethane-1,2-diamine in the presence of benzaldehyde. The desired amino acid derivative 
119 was isolated in a yield of 74%. Next, starting from dimethylamine or N-benzylmethylamine in 








Scheme 40. Synthesis of kynurenic acid (KYNA) Mannich derivatives. 
 
The extension possibility of the reaction was further tested by starting from cyclic secondary 
amines such as morpholine, piperidine, and N-methylpiperazine leading to 121a, 121b, and 121c, 
respectively. As the last representative amines 1,2,3,4-tetrahydroisoquinoline and its dimethoxy 
analogue were chosen as aromatic fused cyclic secondary amines. In these cases, relatively long 
reactions (8 h and 10 h) led to the formation of 122a and 122b. 
 
3.2.2. Substituted KYNA ethyl esters applied in mMr 
 
To test the effect of substituents at positions 5, 6, 7 or 8 on the mMr, derivatives 111b–e 
were reacted with morpholine, as a representative secondary cyclic amine, in the presence of 
formaldehyde. Reactions were carried out in 1,4-dioxane at reflux, yielding 123–126 (Scheme 41). 
Based on the yields, it can be concluded that aryl/alkyl substituents at position 6 or 8 and the 








Scheme 41. Synthesis of 5-, 6-, 7-, and 8-substituted KYNA Mannich derivatives. 
 
3.2.3. Diverse aminoalkylations of the hydroxylated KYNA derivatives 
 
3.2.3.1. 6-Hydroxykynurenic acid ethyl ester 
Based on preceding works, 1,4-dioxane seemed to be the optimal media for the 
substitution reactions of 114a. However, after achieving only moderate conversion (Table 
2, Entry 4) during the mMr of 114a (Scheme 42), the reaction was conducted in other 
solvents including MeCN as aprotic polar solvent, EtOH as protic polar solvent, and 
toluene as aprotic apolar solvent at 80 °C, using 1 equivalent of morpholine and 3 
equivalents of paraformaldehyde (Table 2). 
 
 








Table 2. Screening of solvents in the case of 114a 
Entry Amine 
equiv. 
Solvent T (°C) t 
 
conv.a 127a:127ba 
1 1.0 EtOH 80 30’ 10% 127a 
2 1.0 EtOH 80 1 h 50% 127a 
3 1.0 EtOH 80 2 h 85% 4:1 
4 1.0 1,4-dioxane 80 2 h 70% 1:1 
5 1.0 toluene 80 2 h ~1% – 
6 1.0 MeCN 80 2 h 70% 1:2 
a: determined from the crude NMR spectra 
 
We aimed to investigate the selectivity of the synthesis in ethanol, since this solvent 
enabled the formation of the most homogeneous reaction mixture presumably facilitating 
the highest yield. Although the higher temperature accelerated the reactions, conversions 
were maximized at around 85% (Table 3, Entries 3 and 6). While higher temperature and 
longer reaction promoted the formation of 127b, its share in the isolated products remained 
low this showing high selectivity towards C-3 substitution. 
To further investigate the reactivity of compound 114a, reactions using 2 and 3 
equivalents of morpholine were carried out in EtOH. Faster reactions were observed in 
both cases, reaching a final ratio of 1:1 between 127a and 127b (Table 3, Entries 12 and 
15) further suggesting that the substitution at C-5 is much less preferred relative to that 







Table 3. Screening of temperature and reagent equivalents in the case of 114a 
Entry Amine 
equiv. 
Solvent T (°C) t 
 
conv.a 127a:127ba 
1 1.0 EtOH 100 30’ 45% 4:1 
2 1.0 EtOH 100 1 h 55% 4:1 
3 1.0 EtOH 100 2 h 85% 7:2 
4 1.0 EtOH 150 30’ 60% 4:1 
5 1.0 EtOH 150 1 h 65% 7:2 
6 1.0 EtOH 150 2 h 85% 13:2 
7 1.5 EtOH 80 30’ 60% 4:1 
8 1.5 EtOH 80 1 h 65% 3:1 
9 1.5 EtOH 80 2 h 90% 2:1 
10 2.0 EtOH 80 30’ 60% 15:8 
11 2.0 EtOH 80 1 h 70% 10:9 
12 2.0 EtOH 80 2 h 90% 1:1 
13b 3.0 EtOH 80 30’ 99% 128a 
14 3.0 EtOH 80 1 h 99% 10:1 
15c 3.0 EtOH 80 2 h 99% 1:1 
a: determined from the crude NMR spectra 
b: work-up performed to isolate 127a 
c: work-up performed to isolate 127b 
 
It is worth mentioning that even though the reactions stopped after reaching a ratio of 
1:1 after 2 hours, using increased amounts of amine halted the formation of 127b. This 
indicates a possible basic inhibition of the reaction preventing the formation of the reactive 
iminium ion. This view is in accord with the mechanism proposed for the Mannich-type 
condensation studied in this contribution. On the basis of solvent screening, the selectivity 
towards the formation of the disubstituted derivative can be increased by using aprotic 
solvents. Comparing the effect of MeCN to that of toluene and 1,4-dioxane suggests that 
an increased polarity might also increase this selectivity indicating the involvement of 
ionic species in the crucial regioselective coupling as discussed below. 
 
3.2.3.2. 5-Hydroxykynurenic acid ethyl ester 
On the basis of the results of the reactions performed with compound 114a, the first 
mMr starting from 114b was carried out in EtOH (Scheme 43). Since the reaction featured 
moderate conversion (Table 4, Entry 3), the mMr was repeated using the other three 
solvents, showing lower conversion rates. Considering similarity in selectivity with 114a, a 
detailed investigation with EtOH as protic polar solvent was performed. During the 







C-3, C-6 disubstituted derivative formed only upon using prolonged reactions. It is 
interesting to note that in the case of 128a, the hydrolysis of the ester function did not take 
place, while in the case of compound 128b the free acid was isolated. 
 
Scheme 43. mMr of compound 114b using morpholine and paraformaldehyde 
 
Table 4. Screening for solvent in the reaction of 114b 
Entry Amine 
equiv. 
Solvent T (°C) t 
 
conv.a 128a:128ba 
1 1.0 EtOH 80 30’ 50% 3:1 
2 1.0 EtOH 80 1 h 70% 2:1 
3 1.0 EtOH 80 2 h 70% 2:1 
4 1.0 1,4-dioxane 80 2 h 60% 1:1 
5 1.0 toluene 80 2 h 55% 5:3 
6 1.0 MeCN 80 2 h 65% 2:1 
a: determined from the crude NMR spectra 
 
Formation of 128a can be promoted by using higher temperature and shorter reaction, 
as a prolonged reaction led to the appearance of 128b, even using equivalent amount of 
reagents. With 3 equivalents of amine reagent, full conversion of 114b was achieved after 
30 minutes with a 128a:128b distribution of 4:1 (Table 5, Entry 13), that could be 
increased to 1:4 in a 2-hour reaction (Table 5, Entry 15). Concluding the outcome of the 
reactions, 114b features higher reactivity at position C-6 than at position C-3. However, 
similar to 114a, disubstitution of 114b can also be promoted by using longer reactions 







Table 5. Screening of temperature and reagent equivalents in the case of 114b 
Entry Amine 
equiv. 
Solvent T (°C) t 
 
conv.a 128a:128ba 
1 1.0 EtOH 100 30’ 40% 128a 
2 1.0 EtOH 100 1 h 70% 12:1 
3 1.0 EtOH 100 2 h 70% 6:1 
4 1.0 EtOH 150 30’ 90% 128a 
5b 1.0 EtOH 150 1 h 95% 128a 
6 1.0 EtOH 150 2 h 99% 10:1 
7 1.5 EtOH 80 30’ 40% 10:3 
8 1.5 EtOH 80 1 h 80% 7:1 
9 1.5 EtOH 80 2 h 90% 2:1 
10 2.0 EtOH 80 30’ 90% 4:1 
11 2.0 EtOH 80 1 h 95% 2:1 
12 2.0 EtOH 80 2 h 99% 1:1 
13 3.0 EtOH 80 30’ 99% 4:1 
14 3.0 EtOH 80 1 h 99% 1:1 
15c 3.0 EtOH 80 2 h 99% 1:4 
a: determined from the crude NMR spectra 
b: work-up performed to isolate 128a 
c: work-up performed to isolate 128b 
 
3.2.3.3. 7-Hydroxykynurenic acid ethyl ester 
The modified Mannich reactions of 114c carried out in EtOH at 80 °C proved to be 
highly facile as indicated by the 80% conversion achieved even in 30 minutes (Scheme 44, 
Table 6, Entry 1). In this acidic phenol derivative, the reactivity of C-8 was found to be 
substantially higher than that of C-3 as indicated by the exclusive formation of 129a 
observed in all experiments using one equivalent of morpholine. It is of note that the 
hydrolysis of the ester function in 129a did not take place similar to that of 128a. 
 
Scheme 44. mMr of compound 114c using morpholine and paraformaldehyde 
 
During reactions carried out employing higher equivalents of reagents, the formation 







detectable only after approximately 1.5–2 hours at 80 °C. As the formation of the products 
seemed to proceed under kinetic control, we attempted to perform a reaction using 
conventional heating for 56 hours that afforded 129b in sufficient amount (Table 6, Entry 
16). 
As the formation of 129b was low even upon using higher temperature or increased 
amount of reagents, solvents tested previously were also investigated. In the case of 
1,4-dioxane (as an aprotic solvent with moderate polarity), a selectivity towards the 
formation of disubstituted derivative 129b was observed (Table 7, Entry 1), while in 
MeCN both 129a and 129b were formed with selectivity slightly shifted towards 129a 
(Table 7, Entry 3). 
 
Table 6. Screening of temperature and reagent equivalents in the case of 114c 
Entry Amine 
equiv. 
Solvent T (°C) t 
 
conv.a 129a:129ba 
1 1.0 EtOH 80 30’ 80% 129a 
2 1.0 EtOH 80 1 h 95% 129a 
3b 1.0 EtOH 80 1.5 h 99% 129a 
4 1.0 EtOH 100 30’ 75% 129a 
5 1.0 EtOH 100 1 h 80% 129a 
6 1.0 EtOH 100 1.5 h 90% 129a 
7 1.0 EtOH 150 30’ –* – 
10 1.5 EtOH 80 30’ 85% 129a 
11 1.5 EtOH 80 1 h 95% 129a 
12 1.5 EtOH 80 1.5 h 99% 129a 
13 2.0 EtOH 80 30’ 85% 129a 
14 2.0 EtOH 80 1 h 90% 129a 
15 2.0 EtOH 80 1.5 h 99% 18:1 
16c 2.0 EtOH 80 56 h 99% 3:10 
17 3.0 EtOH 80 15’ 99% 129a 
18 3.0 EtOH 80 1 h 99% 129a 
19 3.0 EtOH 80 1.5 h 99% 18:1 
a: determined from the crude NMR spectra 
–*: multicomponent reaction, conversion could not be determined 
b: work-up performed to isolate 129a 








Table 7. Screening for solvent in the case for 114c 
Entry Amine 
equiv. 
Solvent T (°C) t 
 
conv.a 129a:129ba 
1 1.0 1,4-dioxane 80 2 h 45% 1:5 
2 1.0 toluene 80 2 h 0% – 
3 1.0 MeCN 80 2 h 70% 2:1 
a: determined from the crude NMR spectra 
 
3.2.3.4. 8-Hydroxykynurenic acid ethyl ester 
Compound 134a has already been described in the literature, synthesized by 
employing benzyl protection of the 8-hydroxy function.108 As a preliminary experiment, 
this reaction has also been carried out, implementing the following optimizations: (i) the 
enamine formation required longer reaction time; (ii) Ph2O as solvent was changed to 
1,2-dichlorobenzene for easier work-up; (iii) the aminoalkylation reaction required much 
higher reaction temperature; (iv) during the reduction step with platinum/carbon catalyst, if 
the reaction was kept under H2 gas as long as described, a decrease in yield was observed. 
This might have been due to the adsorption of the product on the carbon surface that could 
be eluded with shorter reaction time and an immediate work-up (Scheme 45). 
 








Without having any further information about the reactivity of the 8-hydroxy 
derivative, we decided to explore the effect of the unprotected function on the course of the 
reaction. 
Based on our experiences on the synthesis of hydroxy derivatives discussed 
previously, aminoalkylations were first carried out in EtOH (Scheme 46). In all attempts at 
different temperatures complex mixtures were detected but without the formation of 134a. 
Reactions, conducted in the presence of increased equivalents of reagents, also provided 
complex mixtures with only traces of 134b detected in the crude product by 1H-NMR 
(Table 8). 
 
Scheme 46. Synthesis of aminoalkylated xanthurenic acid derivatives 
Table 8. Screening of temperature and reagent equivalents in the case of 117a 
Entry Amine 
equiv. 
Solvent T (°C) t 
 
conv.a 134a:134ba 
1 1.0 EtOH 80 1 h –* –b 
2 1.0 EtOH 100 1 h –* – b 
3 1.0 EtOH 150 1 h –* – b 
4 1.5 EtOH 80 1 h –* 134bc 
5 2.0 EtOH 80 1 h –* 134bc 
6 3.0 EtOH 80 1 h –* 134bc 
a: determined from the crude NMR spectra 
–*: conversion could not be determined 
b: no traces of 134a or 134b was detected 
c: minimal amounts, could not be isolated 
 
After these unsuccessful experiments carried out in EtOH, solvents tested previously 
were investigated as well. In toluene and MeCN the sole formation of 134b was observed, 
while in 1,4-dioxane the reaction yielded the C-3 substituted derivative (134a) as the single 







Table 9. Screening for solvent in the case for 117a 
Entry Amine 
equiv. 
Solvent T (°C) t 
 
conv.a 134a:134ba 
1 1.0 1,4-dioxane 80 2 h 80% 134a 
2 1.0 1,4-dioxane 100 2 h 90% 134a 
3b 1.0 1,4-dioxane 150 2 h 99% 134a 
4 2.0 1,4-dioxane 150 2 h 99% 134a 
5c 2.0 toluene 80 1 h 99% 134b 
6 2.0 MeCN 80 2 h 99% 134b 
a: determined from the crude NMR spectra 
b: work-up performed to isolate 134a 
c: work-up performed to isolate 134b 
 
3.2.3.5. DFT calculations on the reactivity of HO-KYNA derivatives 
In order to rationalize the marked regioselectivity patterns observed in the modified 
Mannich reactions of a systematic selection of kynurenic acid esters, we undertook a series 
of comparative DFT calculations carried out with B3LYP functional109–111 using 6–31 
+G(d,p) basis set.112 Computations were supported by the IEFPCM solvent model113 with 
dielectric constant ε=24.5 to represent the polarity of ethanol employed as solvent in most 
experiments. The possible sequences of the competitive Mannich condensations 
accompanied by the hydrolysis of the ester residue are exemplified by the transformations 
of 6-hydroxykynurenic acid ethyl ester 114a (Figure 5). 
The mechanistic picture, accounting for the experimentally observed regioselectivity 
and ester hydrolysis, represented by the reaction pathways applied for the modified 
Mannich reactions of 114a, can be extended to analogous multistep transformations of 
other kynurenic esters investigated in this work. However, searching for a reliable 
interpretation of the characteristic dependence of the regioselectivity on the substitution 
pattern, besides the relative thermodynamic stability, the HOMO delocalization and the 
local NBO charges114 were also disclosed for the corresponding anion pairs type 
114/I-114/II as outlined on Figure 5. Since the crucial coupling between iminium ion 135 
and the appropriate anion presumably takes places under simultaneous controls of orbital 
overlap and the electrostatic interaction between the ionic coupling partners, it can be 
established that – in excellent correlation with the structures of the major products of 
primary Mannich-type coupling – the most nucleophilic regions in the optimized structures 
of the more stable anions (framed structures) can be considered as reliably identified 
reactive sites on the basis of NBO charge and HOMO distribution, if they are taken 







fused benzene ring in 128a and 129a do not allow the ester hydrolysis taking place through 
the corresponding quinoidal ketene intermediates. However, regardless of the position of 
the OH group, the neighboring group assistance from the 3-morpholinomethyl substituent 
obviously promotes this hydrolysis. 
Comparative DFT calculations were also performed for two sets of alternative 
chelate-stabilized rotamers of Mannich products with the morpholinomethyl group 
attached on the fused benzene ring (128a/128a_I/128a_II and 129a/129a_I: Figure 6) that 
identified 128a and 129a, respectively, as the preferred isomers in ethanolic solution. 
 








Figure 6. Rationalization of the feasibility and regioselectivity observed in the Mannich 
reactions of 114a–c in terms of the relative thermodynamics, HOMO energy, HOMO 
delocalization, and the local NBO charges of the possible alternative anions generated by 
morpholine and formaldehyde along with the relative thermodynamics of the chelate-








The sluggish reactivity of 117a experienced in EtOH can be associated with the 
HOMO energy level of 117a/III found to be the lowest one in the series of the modelled 
nucleophilic anions and with the electron density in position 3 (ρNBO= –0.382) decreased 
relative to that identified in position 8 for anion 114c/II, the model with somewhat lowered 
HOMO energy level that presented an increased reactivity in EtOH (Figure 7). 
Finally, we assume that the spectacular solvent dependence observed in the 
transformations of 117a can be rationalized by the polarity-controlled feasibility of the ion 
pairs 117a/III-135 and 134a/III-135, the active coupling components of the first and 
second Mannich-like reactions, respectively. Accordingly, the changes in free energy 
associated with the primary ion pair generating equilibrium condensation steps that involve 
117a and 134a, were assessed (Figure 7). In accord with the general expectations, the 
results (Figure 7) indicate that in the relatively polar ethanol and acetonitrile the formation 
of reactive ion pairs 117a/III-135 and 134a/III-135 is substantially more favorable than in 
the much less polar dioxane and toluene. Although this view is in accord with the failure of 
the second coupling step of the sequential Mannich reactions, attempted in dioxane 
affording 134a and with the ready formation of 134b via 134a in acetonitrile, the ΔG 
values calculated for the ion-pair-forming condensations taking place in ethanol and 
toluene apparently contradict to the experimental results referring to a definite inhibitory 
effect of the more polar solvent and to the facilitating effect of the less polar one. This 
apparent contradiction can partly be resolved by taking donor–acceptor interactions of 
iminium cation 135 with the solvent molecules into account (Figure 7). Thus, among the 
solvents tested, toluene seems to be the one with the most decreased capability to 
deactivate iminium ion 135 allowing a relatively facile Mannich-like couplings of the ion 
pairs. It is also noteworthy that in both anions the HOMO delocalization and the local 
NBO charges are practically invariant to the polarity of the environment, while the HOMO 
energy level is substantially higher in the less polar solvents than in the more polar ones 
suggesting that these species, present even in low concentration in dioxane and toluene, 
display significant nucleophilicity enhanced relative to that predictable in ethanol and 
acetonitrile. These conclusions highlight the significance of HOMO level influencing anion 








Figure 7. Rationalization of the marked solvent effect observed for the regioselective 
sequential Mannich reactions of 134a in terms of: (i) the solvent-dependent changes in free 
energy accompanying the conversions leading active ion pairs 117a/III-135 and 134a/III-
135, respectively; (ii) HOMO energy of the anions; (iii) interactions of the iminium ion 
135 with the solvent molecules. 
 
3.2.4. Extending the mMr to amide derivatives 
 
It has been suspected that multiple cationic centers together will contribute to the biological 
effect with a greater magnitude. Thus, the synthesis of 149c and 150c containing two such 







orders, the synthesis can be achieved by applying two different synthetic pathways: 
aminoalkylation followed by amidation (route A) and a reverse reaction sequence (route B). 
During route A, for the aminoalkylation of 111a, morpholine as a representative secondary 
cyclic amine with formaldehyde was used to form the iminium salt that would attack the C-3 
position on the KYNA skeleton. Afterward, the amidations of 121a were achieved in 
dimethylformamide through the activation of the free carboxylic group with N,N′-
diisopropylcarbodiimide (DIC). During the reactions, 1-hydroxybenzotriazole hydrate (HOBt) was 
also used to generate an active ester intermediate and further improve the yield (Scheme 47). 
 
Scheme 47. Synthesis of aminoalkylated KYNA amide derivatives. 
 
For route B, the starting amides 151 and 152 were synthesized by direct amidation of the 
ethyl ester of KYNA (111a) with N,N-dimethylethane-1,2-diamine (to achieve 151) or with 2-
(pyrrolidin-1-yl)ethanamine (to achieve 152, Scheme 48). Furthermore, to suffice a wider 
evaluation of structure-effect connections, the synthesis of compound 153 was also carried out in a 








Scheme 48. Synthesis of KYNA amide derivatives. 
 
During the mMr, beside morpholine, the use of pyrrolidine and piperidine as secondary 
amines provided derivatives that could later be investigated in vitro for a deeper understanding of 
structure–activity relationships. Compounds 151 and 152 were aminoalkylated with 154a–c in the 
presence of formaldehyde, resulting in aminoalkylated KYNA derivatives 149a–c and 150a–c, 
respectively (Scheme 49). 
 
Scheme 49. Synthesis of C-3 aminoalkylated KYNA amides. 
 
For further investigation, the synthesis of 156, with an alternative amidation via the 








Scheme 50. Synthetic pathways to obtain aminoalkylated KYNA amide 156. i) morpholine, 
CH2O, 1,4-dioxane, reflux (87%); ii) NH3/MeOH, r.t. (88%). 
 
A comparison of the overall yields obtained for 156 and those found for 149c and 150c by 
using the two approaches shows that amidation followed by aminoalkylation (route B) resulted in 








3.3. Biological evaluations on synthesized amides and aminoalkylated 
derivatives 
 
The biological evaluations described in this section were carried out by our co-operating and 
co-author partners. The acquired results show the importance of the synthetic transformations 
carried out and were deemed worthy of mentioning in a separate paragraph. 
As KYNA has poor central nervous system penetration, novel strategies are needed to take 
advantage of its important neuroprotective effects. Among several possible approaches115 the 
synthetic method, i.e., chemical modification of KYNA to obtain compounds with similar 
biological effects, but significantly improved ability to cross the cerebral endothelial cells forming 
the blood–brain barrier, has been carried-out in cooperation with Vécsei et al. During an in vitro 
model system mimicking the in vivo anatomical structure of the blood–brain barrier (BBB) that is 
suitable for drug testing,116,117 the permeability of selected, newly synthesized derivatives (149a–c, 
150a–c) have been assessed beside sodium fluorescein as a control compound. 
 
Figure 9. Penetration of KYNA analogues through the BBB. (A) Permeability of KYNA derivates 
after 60 min compared to sodium fluorescein. N = 2, average ± SD (ANOVA and Bonferroni's 
post hoc test). * p  < 0.05 (149c and 150c: significant difference compared to all other groups; 
significant difference between 149a and 150b or 150a). (B) Permeability coefficients of KYNA 







All of the above-mentioned analogues crossed the BBB more efficiently than sodium 
fluorescein. Furthermore, the permeability of 149c and 150c was significantly higher than the 
permeability of other analogues (Figure 9). 
Next 149c, a promising biologically active compound, was further investigated. Its 
permeability was compared with that of KYNA, xanthurenic acid, and 134a its analogue, which is 
under patent protection.118 149c had a significantly higher permeability through the in vitro BBB 
model than KYNA, xanthurenic acid or 134a both at 30 min and 60 min time points. Differences 
among permeability of KYNA, xanthurenic acid, and 134a were not statistically significant 
(Figure 10). 
In line with this comparison, we hypothesize that aminoalkylation at C-3 facilitates BBB 
penetration with the morpholinomethyl functional group showing the best results. These results 
are in line with in vivo data showing that peripherally administered 149c can reach sufficient 
concentration in the brain, since it is able to inhibit epileptiform activity.119 
 
Figure 10. Penetration of 149c through the BBB. (A) Permeability of 149c after 30 and 60 
min compared to KYNA, xanthurenic acid, and its analogue, 134a. N = 3, average ± SD. * p < 
0.01 (149c: significant difference compared to all other groups, in both time-points). (B) 
Permeability coefficients of 149c, xanthurenic acid and 134a after 30 and 60 min compared to 
KYNA. 
 
Besides investigating their BBB penetration, several compounds have also been used in 







investigations aiming toward the study of their electrophysiological effects or their effects on 
tumor necrosis factor alpha (TNF-α) production. 
In the case of compounds 149c, 150c, 152, and 153 compared to KYNA, 151 showed 
similar effect on a model system of orthodromic stimulation of the Schaffer 
collateral/commissural pathway. The effect of 153 was fundamentally different. Its administration 
in higher concentration resulted in the facilitation of the amplitudes, while in lower concentration, 
its effect was slightly inhibitory. Aminoalkylation also resulted in different electrophysiological 
characteristics. In the case of 149c, only a slight increase could be observed in higher 
concentration and a weak inhibition in low concentration, none of which was significant. In the 
case of compound 150c, the results were not consistent, but in high concentration most of the 
results showed serious decrease in the amplitudes while in other cases the inhibition was smaller. 
In low concentration there was hardly any effect (Figure 11). 
 
Figure 11. Effects of KYNA and its derivatives (138, 140, 136c, 137c), respectively on the field 
excitatory postsynaptic potentials (fEPSPs) recorded in CA1 region of hippocampus. 
 
In another study, the anti-inflammatory effect of KYNA and derivatives 149c, 150c and 
151–153 was investigated. First the TNF-α production of U-937 cells stimulated with heat-
inactivated Staphylococcus aureus was assessed showing inhibition in all cases (Figure 12). The 
effect of the analogues was also compared in equimolar concentration on the TNF-α production, 
when the inducer was Chlamydia pneumoniae. In these experiments, KYNA, 151, and 152 







decreased it (Figure 13). The different behavior in the case of infection with C. pneumonia might 
be due to structural differences. Namely, the morpholinomethyl function at C-3 resulting in 
subgroups of (i) compounds with one cationic center (151–153) and (ii) compounds with two 




Figure 12. TNF-α levels attenuated by 
KYNA and KYNA analogues in SA1 
stimulated U-937 cells. 
Figure 13. Effect of KYNA and KYNA 
analogues on TNF-α production in U-937 
human monocytic cells stimulated by 
Chlamydia pneumoniae. 
 
Finally, it has also been investigated by patch-clamp technique, how KYNA and derivatives 
121a and 149c have any adjustments on different ionic currents in pituitary GH3 cells and 
hippocampal mHippoE-14 neurons. KYNA and 149c increased the amplitude of M-type K+ 
current [IK(M)] and concomitantly enhanced the activation time course of the current. In cell-
attached current recordings, addition of KYNA raised the open probability of M-type K+ 
channels, along with increased mean open time of the channel. In hippocampal mHippoE-14 
neurons, the addition of KYNA also increased the IK(M) amplitude effectively. Taken together, 
the actions observed would be one of the noticeable mechanisms through which they modulate 
functional activities of excitable cells occurring in vivo. 
Taking in consideration that, as mentioned above, compound 149c achieved the highest 
permeability on a BBB model, it is reasonable to propose that these derivatives through their 
stimulation of IK(M) could be beneficial for the treatment of different psychiatric or neurological 







TSG-6 expression following activation with bacterial components could participate in the 
suppression of inflammatory cytokines, such as TNF-α. As KYNA and, in particularly, KYNA 











1. The Conrad–Limpach procedure used in the synthesis of the ethyl ester of KYNA and its alkyl-, 
aryl-, and halogen-substituted derivatives has been optimized using two steps: (i) column-
chromatographic purification of the intermediate enamines and (ii) using 1,2-dichlorobenzene for 
the ring-closure reaction resulting in an easier work-up. For the synthesis of hydroxylated KYNA 
derivatives, beyond extending the reaction and using the optimized Conrad–Limpach procedure, a 
microwave-assisted alternative procedure catalyzed by p-TsOH was also applied. 
 
2. Based on the structural similarities between 1-naphthol and kynurenic acid, the reactivity of KYNA 
was investigated in a modified Mannich-type reaction. Aminoalkylations at the C-3 position have 
been achieved applying benzaldehyde and formaldehyde with different primary, secondary, cyclic 
and acyclic amines. This synthesis method was then extended by using the alkyl-, aryl-, and 
halogen-substituted KYNA derivatives in mMr with morpholine and formaldehyde as representative 
amine and aldehyde, respectively. The reactions resulted in the formation of C-3-substituted 
derivatives. It was also concluded that the substituents at the B ring do not influence significantly the 
reactivity of KYNA ester precursors. 
 
3. The scope and limitations of mMr were also studied starting from hydroxy-functionalized 
derivatives. Through a systematic investigation of substitutions applying morpholine and 
paraformaldehyde as representative reagents,  mono- and disubstituted derivatives were synthesized. 
Product selectivity and regioselectivity were rationalized by DFT calculations disclosing HOMO 
distribution and NBO charges on the potential nucleophilic centers in the anion of the appropriate 
KYNA ester assumed to be active components towards the iminium ion intermediate. 
 
4. Amines bearing tertiary nitrogen needed for biological activity towards the central nervous 
system were used to synthesize amide derivatives of KYNA. These amides were then used to 
further extend C-3 aminoalkylations using cyclic and acyclic secondary amines and 
formaldehyde. The synthesized amides and aminoalkylated derivatives have been investigated 
in studies concerning their blood-brain-barrier penetration, their electrophysiological effects 
on different hippocampal cultures, and their effect on TNF-α production in the case of S. 







morpholine-methylated N-2-(dimethyamino)ethylamide analogue 149c showed the most 
promising properties for further investigations. 
 
5. The two different synthetic pathways leading to aminoalkylated amides, namely 
aminoalkylation followed by amidation (route A) and a reverse reaction sequence (route B), 
have been investigated. A comparison of the overall yields to obtain three representative 
aminoalkylated amide derivatives showed that amidation followed by aminoalkylation (route 
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